Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors

Next Previous
Trial Profile

Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Befovacimab (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions
  • Sponsors Bayer

Most Recent Events

  • 01 Sep 2022 Results assessing safety of multiple escalating doses of befovacimab in individuals with severe haemophilia A/B with or without inhibitors, published in the Haemophilia.
  • 05 Nov 2019 Status changed from active, no longer recruiting to discontinued.
  • 05 Nov 2019 This trial has been completed in Austria, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top